Axsome Settles SUNOSI Patent Litigation, Clears Path for Generics in 2040

Event summary

  • Axsome Therapeutics resolved all patent litigation related to SUNOSI (solriamfetol) through a settlement agreement.
  • Five generic drug manufacturers will gain the right to sell generic versions of SUNOSI starting September 1, 2040, or March 1, 2040, depending on pediatric exclusivity.
  • The settlement requires regulatory review by the FTC and DOJ.
  • No remaining patent litigation related to SUNOSI is pending.

The big picture

The settlement resolves long-standing patent disputes, ensuring market exclusivity for SUNOSI until at least 2040. This move aligns with broader industry trends of biopharmaceutical companies securing intellectual property while preparing for eventual generic competition. The resolution also underscores the strategic importance of regulatory approval in shaping long-term market dynamics for CNS treatments.

What we're watching

Generic Entry Timing
The pace at which generic competition emerges will impact SUNOSI's market exclusivity and revenue potential.
Regulatory Approval
Whether the FTC and DOJ will approve the settlement agreement as submitted.
Market Impact
How the resolution of patent litigation affects Axsome's strategic positioning in the CNS disorder treatment space.